Product Name: KinSub1DDYYV
Product Number: PE-01AGV95
Size: 200 µg      Price:99.00
      $US
Peptide Name: KinSub1DDYYV

Product Use: For assaying the phosphotransferase activity of Activin receptor type-1B (ALK4, UniProt ID P36896). The KinSub1DDYYV peptide demonstrated medium phosphotransferase activity with Brk, and exhibited medium specificity when assayed with over 200 other protein kinases. A listing of other kinases that show appreciable phosphotransferase activity towards this peptide are listed in Table 1.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: KinSub1DDYYV was originally identified using a microarray with peptides that were predicted as optimal substrates for 500 human protein kinases with a proprietary algorithm developed at Kinexus with our academic partners.

Peptide Sequence: GGRGDDYYVCVGGGY

Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 1536.6 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: Brk

Scientific Background: ALK4 is one of several protein kinases that can phosphorylate KinSub1DDYYV. Human ALK4 is a protein-serine/threonine kinase of 505 amino acid length, with a predicted molecular mass of 56,807 Da. It is a member of the TKL group of protein kinases in the STKR family, and Type1 subfamily. This kinase is highly expressed in most of the tested human tissues (including adrenals, brain, kidney, liver, lung, pituitary, prostate, salivary gland, spinal cord, spleen, testes, thymus, thyroid, trachea, and uterus), but many human tissues have not been examined. Orthologues of ALK4 are highly conserved in vertebrates, including amphibians. ALK4 is activated by binding activin, which induces heterodimerization and autophosphorylation. It is part of a complex consisting of AIP1, ACVR2A, ACVR1B and SMAD3. Truncated ALK4, which is predominantly expressed in human pituitary adenomas, functions as a dominant negative receptor to interfere with wild-type receptor function and block the antiproliferative effect of activin, possibly contributing to development of human pituitary tumours (1). ALK4 is able to mediate Nodal signalling in the presence of Cripto during vertebrate development (2).